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I. One of the most interesting developments in our knowledge of gastric mucosal
pathobiology has been the recognition ofthe relationship between Helicobacterinfection,
chronic gastritis, induction oflymphoid follicles in the mucosa (MALT)C and gastric lym-
phoma. Difficulties in distinguishing histologically between florid reactive lymphoid
hyperplasia, sometimes termed "pseudolymphoma," and lymphoid neoplasia have long
been recognized. More recently, monoclonality of lymphoid proliferations and the pres-
ence ofgene rearrangements have been taken as evidence oftransformation to a neoplas-
tic state, and molecular techniques have increased our sensitivity overhistology in detect-
ing these lesions. However, the demonstration by Isaacson's group, subsequently con-
firmed by others, that early MALT lymphomas, diagnosed by morphologic and molecular
criteria are not autonomous but are driven by specific Helicobacter antigens in the pres-
ence ofTcells and regress upon elimination ofthe Helicobacterinfection, is both intrigu-
ing and important [1, 2]. First, ithas altered ourmanagement ofpatients with early MALT
lymphomas ofthe stomach. Second, it raises as yet unanswered questions about the long-
term outcome ofthese lesions: forexample, following regression ofthe initial tumor, does
a population of"tumor" cells remain in the mucosa with the potential for re-emergence if
the bacterium is incompletely eradicated or if reinfection occurs, as a few early reports
suggest [3]. How can we distinguish reliably between "early" or antigen-dependent lym-
phoid proliferations and those that are truly autonomous and that, therefore, will not
respond to antibiotic therapy? Moreover, it prompts a semantic question concerning the
definition of neoplasia: recognizing that its development is a multi-step process, how do
we now define when neoplastic transformation has occurred in this setting? Are these
early MALT "lymphomas" true neoplasms, or are they merely reactive monoclonal lym-
phocytic reactions to a persistent foreign antigen, best defined as pre-neoplastic? Finally,
it raises fundamental questions as to what molecular changes occur in mucosal B-cells
during the progression from reactive gastritis to low-grade and high-grade maltoma and
how Helicobacterpylori elicits them. The availability ofa mouse model ofHelicobacter-
induced gastric maltomas offers an opportunity to compare the roles ofproducts generat-
ed by Helicobacter and those produced by inflammatory cells in a similar system [4]. In
association with studies on readily accessible human gastric biopsy tissue, this may lead
to elucidation of the pathogenesis ofthis interesting lymphoproliferative process.
II. The morphologic changes that occur in the mucosa affected by chronic gastritis
have been well recognized for many years, although the histologic terminology has been
a matter of some dispute. Chronic inflammation, as seen in Helicobacter-associated and
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autoimmune gastritis, may lead to profound changes in the acid secreting mucosa, culmi-
nating in complete loss ofseveral functionally important components ofthe epithelial cell
population, notably the chiefand parietal cells. The process by which this occurs is poor-
ly understood, and it is not clear why residual epithelial stem cells fail to differentiate in
a normal fashion. Moreover, it is not known with certainty ifregeneration of acid-secret-
ing glands can occur in this setting once the inflammatory processes are ablated, or ifgas-
tric atrophy is a fixed condition, as one study suggests, in which no regression ofatrophy
was detected during up to one year following eradication ofHelicobacter [5]. A remark-
able feature ofthe atrophic gastric mucosa is its propensity to develop intestinal metapla-
sia. Although several varieties ofintestinal metaplasia are described, all are characterized
by epithelial differentiation that is more akin to that seen in the small intestine (often with
Paneth cells, absorptive enterocytes and goblet cells) or in the large intestine, as ifthe dif-
ferentiation program in the stem cell had been switched. Whether such differentiation
packages are under the control ofhomeobox genes is not known. However, elucidation of
the mechanisms controlling this process is important, as it is well-recognized that intesti-
nal metaplasia ofthe incomplete orcolonic type is aprecursorofthe intestinal type ofgas-
tric andenocarcinoma. Moreover, atrophic gastritis is itself a usual prerequisite for ente-
rochromaffin-like (ECL) cell hyperplasia or neoplasia in the mucosa of the gastric
body/fundus.
III. Gastric epithelial dysplasia, defined as an unequivocal neoplastic transformation,
is being increasingly recognized. At present, the diagnosis of dysplasia rests on morpho-
logic features, and it is commonly evaluated as being high- or low-grade. The manage-
ment of patients with a diagnosis of gastric dysplasia is still a matter of controversy.
Weinstein has recommended that all patients with this diagnosis should have extirpation
of the dysplastic mucosa, either by endoscopic mucosectomy or by resection, following
careful mapping of its extent by endoscopy with multiple biopsies [6]. It is generally
accepted that gastrectomy is advisable in cases ofhigh-grade gastric dysplasia. However,
since there is much subjectivity in diagnosing dysplasia, and in particular in distinguish-
ing between low-grade dysplasia and reactive atypia, many favor a more conservative
approach in cases of low-grade dysplasia, with careful follow-up, repeat evaluation with
multiple biopsies and independent review of the biopsy material by an experienced gas-
trointestinal pathologist. If low-grade dysplasia is confirmed, extirpation would, at pre-
sent, appear to be the treatment ofchoice, since low-grade dysplasia has been reported to
progress to carcinoma within only two years ofdiagnosis [7].
IV. While it is well recognized that ECL cells are increased in prominence in the
mucosa of the body/fundus in atrophic gastritis, there is dispute as to how this occurs.
Possibilities include proliferation ofECL cells, proliferation ofprecursor stem cells in the
gastric gland necks, a shift in the differentiation spectrum ofexisting uncommitted epithe-
lial cells towards the ECL phenotype, increased longevity ofECL cells (e.g., by inhibition
of ECL cell apoptosis) and selective destruction of other epithelial cell types resulting in
a relative increase ofECL cells [8]. Loss of other epithelial elements in atrophic gastritis
complicates quantitation ofabsolute ECL cell numbers ormass, butin patients with severe
hypergastrinemia (1,000-10,000 pg/ml) ofotheretiologies, there is a clear increase in vol-
ume density, cross-sectional area and number ofprofiles ofECL cells in microscopic sec-
tions [9]. No evidence ofECL cell proliferation was found in the normal human stomach
or in gastritis in a recent study in which double-staining with the endocrine cell marker
chromogranin A and the proliferation marker Ki67 was performed, suggesting that the
ECL cells may be terminally differentiated [10]. However, ifECL cell precursors that had
not yet synthesized chromogranin were proliferating, they would not have been detected
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in this analysis. It has been suggested that in chronic gastritis, when epithelial cells
expressing class II antigens are being subjected to attack by cytotoxic T-cells, the ECL
cells, which lack these antigens, may survive unimpaired. Such a mechanism might
account for the increased prominence of ECL cells in chronic gastritis, especially the
micronodular form, but it would not explain the diffuse hyperplasia observed in patients
with gastrinoma and severe hypergastrinemia. It seems likely, therefore, that gastrin has
an effecteither on proliferation ofECL cells ortheirprecursors, or on the longevity ofdif-
ferentiated ECL cells. The reversibility of ECL cell hyperplasia in rats in which hyper-
gastrinemia is controlled supports this concept. Endocrine cells generally are long lived
and have aproliferation rate that is low relative to many othercell populations, and, there-
fore, a very slight (and potentially undetectable) increase in the rate ofproliferation, or a
subtle increase in longevity of these cells, could have marked effects on their numbers.
Nevertheless, at some point in the development ofECL cell neoplasia it is evident that a
proliferative process must occur, leading to invasion through the muscularis mucosae, to
the development ofaggregates ofthese cells in the sub-mucosa and ultimately to metasta-
tic dissemination. Further clarification ofthese events is needed.
ECL carcinoids are exclusively found in the nonantral mucosa of patients with type
A autoimmune atrophic gastritis or with the multiple endocrine neoplasia (MEN-1) syn-
drome (i.e., in the presence ofhypergastrinemia and a genetic predisposition or immuno-
logical factors). They are ofessentially benign nature. In contrast, sporadic gastric carci-
noids are mostly multihormonal and gastrin independent (i.e., found in normogastrinemic
patients without any background gastropathy) [11, 12]. They are not restricted to the
nonantral mucosa and often behave like neuroendocrine carcinomas.
Omeprazole therapy results in hypergastrinemia, but to date, there have been no
reports of the development of carcinoidosis in patients using this medication. In one
detailed study of the effects of five-year omeprazole therapy, ECL cell hyperplasia
occurred in aproportion ofpatients but seemed to be more closely associated with chron-
ic gastritis than with the use ofthe drug; in no case was ECL cell dysplasia observed [13].
In chronic gastritis, the increase in ECL cells typically develops over a very long period
oftime. It is possible that more prolonged use ofomeprazole will be seen to have similar
effects. A minority ofpatients on omeprazole have significant hypergastrinemia (500-800
pg/ml). Usually, they also have advanced atrophic gastritis and may, therefore, be at
increased risk ofECL cell proliferation. It has been suggested thatHelicobactershould be
eliminated in these patients since it increases the rise in gastrin due to omeprazole.
V. The complex components ofthe interaction ofH. pylori with the gastric mucosa
are beginning to be dissected and unraveled. Evidence is accumulating that down-regula-
tion of somatostatin may be an important factor in this process [14]. Decreased secretion
of somatostatin would mean de-inhibition of the G-cells and, thus, explain the hypergas-
trinemia ofpatients with antral gastritis due to H. pylori. Whether this occurs directly, for
example through production of an H3 agonist as suggested by Megraud, as a secondary
response to inflammation as seen in the rectum in proctitis, or as a result of the effect of
virulence factors such as cagA and vacA on D-cells, is unknown. Also, direct stimulation
of the gastrin producing G-cells by inflammatory cytokines has been recently described
[15].
As more has been learned about the apparent virulent factors ofH. pylori, it has been
become evident that there is marked variation in their expression in different strains; this,
and the potential for studying strains deleted ofspecific virulence factors, opens the way
for distinguishing between those factors that are significant in the pathogenesis ofchron-
ic gastritis from those that are not, and for investigating the mechanisms involved. On the
other hand, information that is emerging concerning the inflammatory response to H.
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pylori, both in terms ofcellular elements and cytokines, will also contribute to our under-
standing of the processes by which mucosal injury is mediated and may contribute to the
development of strategies for vaccine production. In this context, it has been suggested
that mucosal injury in H. pylori gastritis is due to an inappropriate Thl response, and that
if a Th2 response is provoked the infection could be satisfactorily cleared without signif-
icant residual mucosal damage [16].
In patients with duodenal ulcer and H. pylori gastritis, unstimulated acid secretion
returns to normal following Helicobacter eradication [17]. Currently, results relating to
maximally stimulated acid secretion in duodenal ulcer patients are conflicting. Data from
patients without duodenal ulcers are not available. After Helicobacter eradication, both
the response of gastric acid secretion to gastrin releasing peptide and the serum gastrin
levels decrease, though the fall in gastrin is markedly variable from patient to patient. The
reasons for this variability in the gastrin response are unclear, but may be related to
Helicobacter load, the duration ofinfection or the severity ofthe gastritis. Gastrin releas-
ing peptide is a neurotransmitter (not a hormone) and has the capacity to stimulate gastrin
and somatostatin secretion ifinfused intravenously. In the case ofH. pylori infection (i.e.,
impaired somatostatin response), GRP has an unrestrained effect on gastrin and gastric
acid secretion, which is reversed after H. pylori eradication [18].
Despite the remarkable advances in our knowledge ofthe pathobiology ofthe gastric
mucosa since the discovery ofH. pylori, the complexities ofthe immune response to this
pathogen and of the cross-talk between the mucosal inflammatory, stromal and epithelial
cells and their cytokines and hormones remain a formidable challenge.
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